LAURA Trial (NEJM/ASCO 2024): Osimertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Discover the game-changing results of the LAURA trial, a pivotal Phase III study evaluating osimertinib as consolidation therapy following definitive chemoradiotherapy in patients with Stage III EGFR-mutated non-small cell lung cancer (NSCLC).

Presented at ASCO 2024 and published in the New England Journal of Medicine (NEJM, 2024), this study explores whether targeted therapy can delay progression and improve survival in this historically underserved population.

Targeted Therapy | EGFR | NSCLC | Stage III | Osimertinib | Lung Cancer | Consolidation Therapy

#LAURATrial #Osimertinib #EGFR #NSCLC #StageIIILungCancer #ASCO2024 #NEJM2024 #TargetedTherapy #LungCancerResearch #ClinicalTrials #Oncology
Category
Oncology
Be the first to comment

Up Next